Proxa LabsMethodology

How Intelligent Commercial Readiness Works

Article summary

Biopharma has never had a dependable way to know whether its field team can actually sell a new product. Training completion has stood in for that answer, mostly because nothing else could be counted across a few thousand reps. That constraint has lifted. Capability can now be measured directly, through a methodology called Intelligent Commercial Readiness that treats measurement as a standing practice rather than a launch-week event. What follows is how it runs, and what it gives a learning leader who commits to it.

Every time I signed off that a field force was ready for launch, my evidence was a completion report and my own read on how the training had gone. That was true when I was running global commercial learning at a large pharma, and it is true for most of the leaders I talk to now. A completion report describes one week in March. It says nothing about whether a rep can still handle the payer objection in September when a physician pushes back, and I had no way to find out.


That gap gets expensive. A rep who cannot handle a formulary objection in month one is usually still struggling with it in month twelve, because nothing looks for the problem after certification day. The territory underperforms, the shortfall gets attributed to access or targeting or market conditions, and the same weakness sits uncounted across a dozen other territories. At the end of the year learning cannot show what its work changed, the budget is trimmed, and the next launch gets less support than the one before. Nobody in that sequence does anything wrong, which is exactly why it repeats.

What has changed is that the gap is now closable. Scoring several thousand recorded conversations against a behavioral standard, four times a year, used to exceed the headcount of any training team, so the industry counted completions and inferred the rest. That limit is gone. The timing matters, because most commercial L&D leaders are being asked right now what AI is returning to the business, and very few have an answer that survives a follow-up question. Capability measurement is one of the few that answers with numbers.

Intelligent Commercial Readiness is the practice that produces those numbers. Here is how it runs.

Commercial and learning define what capable means

The practice begins with both functions agreeing on a definition of capability for a specific launch, which is harder than it sounds. Commercial sets the strategy, learning is briefed afterward and asked to build training, and capability itself never gets defined by anyone.


Commercial has to describe what the launch demands of the field: the conversations that decide formulary position, the objections a competitor is raising, the parts of the message that have to survive a skeptical physician. Learning brings the training interpretation of that strategy, meaning what those demands look like as observable behavior, what can realistically be built in the time and budget available, and how capability develops in adults working a territory. What comes out is an agreement on what the field team must be able to do consistently, over time, to create impact.

Four or five capabilities is enough, provided they are written in behavioral terms so performance can be measured against them. One might read: can a rep answer a specific objection accurately, stay inside the label, and keep control of the conversation.

One condition comes with that agreement, which is that commercial has to act on the scores, including the low ones. If most reps cannot yet answer the payer's cost-effectiveness question, three real options sit on the table: adding field support where that conversation carries the most weight, reducing the initial target list to accounts where it carries the least, or moving the launch date. Sending the result back to learning as a training problem instead is the most common way this falls apart.

Reps get scored against those capabilities, every quarter

Training still delivers the knowledge, since reps need mechanism of action, clinical data, and compliant use of the label. What gets added is practice against the specific conversations in the definition, rehearsed in the order a rep will actually hear them and under something close to the time pressure of a real call.


Then the scoring. A rep works through the conversation in simulation, the performance is scored against the standard the two functions agreed on, and the capability that broke down is identified. Managers review a sample to confirm the scoring holds up, which keeps human judgment in the process without asking anyone to grade every rep. What comes out is a score per rep for each capability, and in most organizations that is the first time a training measure and a commercial definition of readiness have appeared together.

One score is not enough, because capability declines without attention. A physician gives a rep ninety seconds, so she drops the probing question and shortens her objection response to fit, and after a few months the shortened version is the only one she still has. Running the assessment quarterly catches that while it is happening. The capability list has to stay fixed so the trend reflects the field team rather than the definition, the assessment should sit alongside the cycle meeting where managers are already reviewing performance, and one person has to own it running on schedule.

After several cycles you have a trend for each capability, broken out by region, and set alongside business results it starts to explain them. Objection handling improving where share is growing, a capability flat in a district whose numbers are also flat. That is the connection between learning investment and commercial performance the function has never been able to demonstrate.

A gap found before the field reaches the territory can still be closed. The same gap found in next year's loss reasons cannot.

Development and coaching follow the individual scores

Traditional training moves an entire cohort through the same content on the same schedule. Capability scores allow something more precise, because the assignment follows the score. A rep weak on access objections works on access objections, while a rep strong there and weak on competitive comparison works on competitive comparison instead. What gets assigned is whatever will move that capability: a practice conversation, time with a manager on a ride-along, a short reinforcement piece, an hour with a colleague who handles it well. Curriculum becomes one option among several rather than the default.


Ten weeks into a launch, a district manager holding these scores can see which rep is strong on access and weak on competitive comparison, which is the reverse, and which is strong enough to be paired with someone struggling. Instead of running one refresher for the whole district, he holds individual conversations about specific behaviors with evidence behind each one. The commercial leader above him gets an answer that has never been available before: whether the field team can execute the strategy, capability by capability, with evidence and a date attached.

Each cycle also feeds the next. What the assessment finds about where reps break down goes back into the material they train on, so the next round is built on what the last one learned rather than on last year's assumptions.

What a learning leader gets out of Intelligent Commercial Readiness

The reasonable pushback is that this adds measurement burden to a function already stretched thin. It does add a step, and what it removes is larger: refreshers delivered to reps who do not need them, ride-along impressions standing in for evidence, and the annual exercise of defending a budget with completion rates.


What it returns is four things.
  • The question becomes answerable. What your team can do today that it could not do six months ago has an answer, with evidence behind each capability.
  • The budget conversation changes shape. Learning spend connects to capability movement, and capability movement sits alongside business results.
  • Launch risk becomes visible while it can still be managed. A gap found before the field reaches the territory can still be closed, and the same gap found in next year's loss reasons cannot.
  • Less time gets wasted on both sides. Reps work on what they actually need, and managers coach from evidence rather than impressions.

Where to start

None of this has to be implemented at once, and the first step costs nothing. Take the next launch on your calendar, put the commercial leader who owns it and the learning leader who will support it in a room for two hours, and write down four or five things a rep has to be able to do, in behavioral terms, with both sides agreeing those are the right four or five. That page is the foundation for everything else, and producing it will tell you quickly whether your organization is ready for the rest.


For most of my career there was no instrument for measuring what a rep can actually do, at scale, on a schedule. That instrument exists now. What it asks for is a definition worth measuring against and the discipline to keep measuring.

At Proxa Labs we built that loop as a connected system: Cue for the learning pathways, Stage for the simulated conversations, Trace for tracking behavior over time, and Forge for turning what the system learns back into the material. If you want to work through what the practice would look like for a specific launch, that is what our Innovation Lab is for. We work it out with teams before anyone commits to a platform.

Proxa Labs
John Royer

John Royer

Managing Partner & President, Proxa Labs

John Royer is Managing Partner & President of Proxa Labs. John spent twenty-five years inside biopharma commercial learning, including global commercial learning leadership at AstraZeneca, before founding Proxa Labs to help organizations close the gap between AI ambition and readiness. Proxa Labs is an advisory-first firm that diagnoses before it recommends.